Targeting Lewis Y (Ley) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: A pilot trial testing two dose levels

Abstract

INTRODUCTION: Lewis Y (Le) is a blood group antigen with robust expression on the surface of epithelial tumors, including small cell lung cancer (SCLC), making it a potential target for antibody-based immunotherapy. 3S193, an immunoglobulin G3 monoclonal antibody, has demonstrated superior specificity, affinity, and cytotoxicity over other anti-Le antibodies. A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies. METHODS: We tested the targeting and pharmacokinetics of hu3S193 in patients with SCLC. Eligibility required progressive SCLC treated with up to three previous ..